SCHEMBL418528

SCHEMBL418528

COC(=O)c1cc(Cl)ccc1NC(=O)c1cccc(-c2cccc3cnccc23)c1

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 7/20 0.78
DGAT2 Q96PD7 2/20 0.53
ROCK2 O75116 5/20 0.47
AKR1C4 P17516 1/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 1/20 0.45
PLAU P00749 1/20 0.45
CHUK O15111 1/20 0.44
ICOSLG O75144 1/20 0.44
ICOS Q9Y6W8 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420949 0.90 SERPINE1 (0.78) SERPINE1DGAT2AKR1C4AKR1C3AKR1C2
SCHEMBL420745 0.89 SERPINE1 (0.82) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL421057 0.89 SERPINE1 (0.81) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL419689 0.88 SERPINE1 (0.78) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL421056 0.88 SERPINE1 (1.00) SERPINE1DGAT2AKR1C4AKR1C3AKR1C2
SCHEMBL417914 0.84 SERPINE1 (0.64) SERPINE1ROCK2AKR1C4AKR1C3AKR1C2
SCHEMBL418419 0.83 SERPINE1 (0.77) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL8442857 0.81 DGAT2 (0.66) SERPINE1DGAT2
SCHEMBL420185 0.79 SERPINE1 (0.77) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL418400 0.79 SERPINE1 (0.60) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DGAT2 3611/4885ROCK2 2808/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DGAT2 3611/4885ROCK2 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.